V
V. Rusch
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 12
Citations - 3273
V. Rusch is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Atezolizumab & Lung cancer staging. The author has an hindex of 7, co-authored 12 publications receiving 2108 citations.
Papers
More filters
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: A Renewed Call to Participation
Dorothy J. Giroux,Paul Van Schil,Hisao Asamura,Ramón Rami-Porta,Kari Chansky,John J. Crowley,Valerie W. Rusch,Kemp H. Kernstine,V. Rusch,Luiz H. Araujo,Paul Beckett,David G. Beer,Pietro Bertoglio,Ricardo Beyruti,Andrea Billè,Vanessa Bolejack,Souheil Boubia,Elisabeth Brambilla,James Brierley,Ayten Kayi Cangir,David P. Carbone,John Crowley,Gail Darling,Frank C. Detterbeck,Xavier Benoit D’Journo,Jessica Donnington,Wilfried Eberhardt,John G. Edwards,Jeremy J. Erasmus,Wentao Fang,Dean A. Fennell,Kwun M. Fong,Françoise Galateau-Sallé,Oliver Gautschi,Ritu R. Gill,Dorothy Giroux,Jin Mo Goo,Seiki Hasegawa,Fred R. Hirsch,Hans Hoffman,Wayne L. Hofstetter,James Huang,Philippe Joubert,Keith M. Kerr,Young Tae Kim,Hong Kwan Kim,Hedy L. Kindler,Yolande Lievens,Hui Liu,Donald E. Low,Gustavo Lyons,Heber MacMahon,Mirella Marino,Edith M. Marom,José-María Matilla,Jan P. van Meerbeeck,Luis M. Montuenga,Andrew G. Nicholson,Anna K. Nowak,Isabelle Opitz,Meinoshin Okumura,Raymond U. Osarogiagbon,Harvey I. Pass,Marc de Perrot,Helmut Prosch,David C. Rice,Andreas Rimner,Enrico Ruffini,Shuji Sakai,Navneet Singh,Amy Stoll-D’Astice,Francisco Suárez,Ricardo Mingarini Terra,William D. Travis,Ming-Sound Tsao,Paula A. Ugalde,Shun-ichi Watanabe,Jacinta Wiens,Ignacio I. Wistuba,Yasushi Yatabe,Liyan Jiang,Kaoru Kubota,Eric Lim,Paul Martin Putora,Akif Turna,Pier Luigi Filosso,Kazuya Kondo,Dong Kwan Kim,Giuseppe Giaccone,Marco Lucchi,Eugene Blackwell,Thomas W. Rice,William D. Travis,Andrew G. Nicholson,M. Tsao,James D. Brierley,Jun Nakajima,Françoise Galateau,Bill Travis,Jim Mo Goo,Luis M. Montuenga,Hong Wei Wang,Katie Nishimura +102 more
TL;DR: The Staging and Prognostic Factors Committee of the IASLC is now issuing a call for participation in the next phase of the project, which is designed to inform the ninth edition of the TNM classification for lung cancer.
Journal ArticleDOI
OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
David P. Carbone,Jivianne T. Lee,Mark G. Kris,I. I. Wistuba,David J. Kwiatkowski,Dwight H. Owen,Paul A. Bunn,Bruce E. Johnson,F. Oezkan,Y. Tang,Edwin R. Parra,Gerard Lozanski,Christopher J. Rivard,Katja Schulze,Alan Nicholas,A. Johnson,J. Grindheim,David S. Shames,S. Phan,Eric M. Toloza,Eric B. Haura,C. Mcnamee,Justin F. Gainor,Alexander Patterson,S. Waqar,Dan J. Raz,Karen L. Reckamp,David J. Finley,V. Rusch,Jamie E. Chaft,J. Abel +30 more
Journal ArticleDOI
MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)
V. Rusch,Jamie E. Chaft,Bruce E. Johnson,I. I. Wistuba,Mark G. Kris,J.M. Lee,Paul A. Bunn,David J. Kwiatkowski,Karen L. Reckamp,David J. Finley,Eric B. Haura,S. Waqar,Robert C. Doebele,Edward B. Garon,Justin D. Blasberg,Alan Nicholas,Katja Schulze,S. Phan,M. Gandhi,David P. Carbone +19 more
Journal ArticleDOI
OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
Filiz Oezkan,Kai He,Dwight H. Owen,Maciej Pietrzak,J.H. Cho,Rhonda Kitzler,Rebecca Pearson,V. Rusch,Jamie E. Chaft,Robert D. Suh,Justin D. Blasberg,Karen L. Reckamp,Dan J. Raz,Peter J. Kneuertz,L. Fiorillo,Edward B. Garon,Alan Nicholas,A. Johnson,Katja Schulze,J. Grindheim,R. Banchereau,S. Phan,Paul A. Bunn,David J. Kwiatkowski,Bruce E. Johnson,Mark G. Kris,I. I. Wistuba,J.M. Lee,Gerard Lozanski,David P. Carbone +29 more
Journal ArticleDOI
A Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) (NRG LU-006).
Andreas Rimner,Chen Hu,V. Rusch,Ritu R. Gill,Charles B. Simone,Marjorie G. Zauderer,Ellen Yorke,Zuofeng Li,Tobias Peikert,R. Voong,Ming Tsao,Jeffrey D. Bradley +11 more
TL;DR: The NRG LU-006 trial as discussed by the authors was the first randomized phase III trial on malignant pleural mesothelioma and evaluated the use of IMPRINT following lung-sparing P/D and chemotherapy.